Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 18-98 / BIG 1-98 

Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumor.

Tamoxifen vs. letrozole vs. tamoxifen followed by letrozole vs. letrozole followed by tamoxifen

DESIGN

Design Trial 18-98

Results & Publications


Presentations


Publications

Study Chair
Prof. Beat Thürlimann - St. Gallen, Switzerland

Statisticians
Anita Giobbie-Hurder
Dr. Zhuoxin Sun


Lead Trial Coordinator
Holly Shaw

Data Managers
Susan Fischer

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg18_BIG1-98@fstrf.org

Date of Activation
March, 1998

Date of Closure
Core Protocol: May 13, 2003
GS/SLP Substudy: February 7, 2003
BMD Substudy: February 7, 2003
New Bone Substudy: January 31, 2007
Fingernail Pilot Substudy: July 31, 2007
Cognitive Function Substudy: May 20, 2008

Final Accrual
Core Protocol: 8028 patients
GS/SLP Substudy: 65 patients
BMD Substudy: 39 patients
New Bone Substudy: 458 patients
Fingernail Pilot Substudy: 16 patients
Cognitive Function Substudy: 135 patients


Results Publications Results & Publications
Other Pathology


News

18.03.2017:
The next IBCSG Annual Meeting will take place in Vienna, Austria on March 18 and 19, 2017 .

15.03.2017:
15th St.Gallen International Breast Cancer Conference 15-18 March 2017 in Vienna/Austria  

30.09.2016:
Benefiz-Gala mit Spitzenkoch Anton Mosimann Freitag 30. September 2016 im Park Hyatt

All News

 
  Print